A Brocard
Overview
Explore the profile of A Brocard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peuvrel L, Quereux G, Saint-Jean M, Brocard A, Nguyen J, Khammari A, et al.
J Eur Acad Dermatol Venereol
. 2015 Nov;
30(2):250-7.
PMID: 26524690
Background: Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown. Objective: To determine the rate of permanent vemurafenib discontinuation due to grade...
2.
Frenard C, Peuvrel L, Jean M, Brocard A, Knol A, Nguyen J, et al.
J Neurooncol
. 2015 Oct;
126(2):355-60.
PMID: 26511495
Unlabelled: Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy...
3.
Haim H, Dutartre H, Saint-Jean M, Brocard A, Peuvrel L, Quereux G, et al.
Ann Dermatol Venereol
. 2015 Mar;
142(4):299-300.
PMID: 25813186
No abstract available.
4.
Guillet A, Brocard A, Bach Ngohou K, Graveline N, Leloup A, Ali D, et al.
J Eur Acad Dermatol Venereol
. 2014 Dec;
29(7):1347-53.
PMID: 25512084
Background: Verneuil's disease is a chronic inflammatory skin disease of the follicles in apocrine glands rich area of the skin (axillary, inguinal, anogenital) and is associated with a deficient skin...
5.
Haim H, Hurault M, Renaud J, Saint-Jean M, Brocard A, Peuvrel L, et al.
J Eur Acad Dermatol Venereol
. 2014 Nov;
30(3):470-2.
PMID: 25376982
No abstract available.
6.
Peuvrel L, Saint-Jean M, Quereux G, Brocard A, Khammari A, Knol A, et al.
J Neurooncol
. 2014 Aug;
120(1):147-54.
PMID: 25098698
Vemurafenib is indicated for the treatment of patients with BRAF (V600)-mutant metastatic melanoma. We studied for the first time the characteristics of brain metastases developed during treatment with vemurafenib in...
7.
Saintes C, Saint-Jean M, Brocard A, Peuvrel L, Renaut J, Khammari A, et al.
J Eur Acad Dermatol Venereol
. 2014 Jul;
29(5):1006-9.
PMID: 24980899
Background: Basal cell carcinoma (BCC) is the most common cancer in humans. Vismodegib, a Hedgehog pathway inhibitor, has proved its effectiveness in treating non-resectable advanced BCC. Aim: However, its action...
8.
Peuvrel L, Chiffoleau A, Quereux G, Brocard A, Saint-Jean M, Batz A, et al.
Dermatology
. 2013 Aug;
226(3):274-8.
PMID: 23941917
Rituximab is an anti-CD20 monoclonal antibody increasingly used in haematology and rheumatology, but also in internal medicine and dermatology. It has a good tolerance profile without known increased risk of...
9.
Leloup P, Nguyen J, Quereux G, Saint-Jean M, Peuvrel L, Brocard A, et al.
J Eur Acad Dermatol Venereol
. 2013 Jul;
28(4):518-20.
PMID: 23859066
No abstract available.
10.
Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Dreno B
Dermatology
. 2012 May;
224(3):204-8.
PMID: 22614575
Temsirolimus belongs to the mammalian target of rapamycin (mTOR) inhibitors, targeted therapies for which indications are booming in oncology. While their tolerance is usually good, mucocutaneous toxicity is the most...